Comparative Pharmacology
Head-to-head clinical analysis: DILOR 400 versus THEOLAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILOR 400 versus THEOLAIR.
DILOR-400 vs THEOLAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular cAMP and cGMP, resulting in bronchodilation and vasodilation.
Theophylline, the active ingredient in THEOLAIR, is a phosphodiesterase inhibitor that increases intracellular cAMP levels, leading to bronchodilation via smooth muscle relaxation. It also has anti-inflammatory effects and may enhance diaphragmatic contractility.
400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.
Initial dose: 300 mg orally every 8-12 hours; titrate based on serum theophylline levels to achieve 5-15 mcg/mL. Maintenance: 400-600 mg/day in divided doses.
None Documented
None Documented
3.1 hours (terminal elimination half-life; may increase in hepatic impairment or congestive heart failure)
Adults: 3-8 hours (mean 5.5); children: 1.5-5 hours; increased in hepatic cirrhosis, heart failure, and COPD; decreased in smokers
Renal (70% unchanged), hepatic metabolism (30%)
Renal (10% unchanged); hepatic metabolism (90%) with metabolites excreted in urine
Category C
Category C
Bronchodilator
Bronchodilator